Introduction
Nonconvulsive status epilepticus (NCSE) often manifests as altered consciousness accompanied with subtle focal motor twitches or ambiguous behavior changes, and the diagnosis has to be based on electroencephalography (EEG). 1, 2 It is easily misdiagnosed clinically without evidence of continuous epileptiform activities on EEG, and attempts to terminate NCSE are frequently delayed. Unfortunately, a number of such cases with prolonged and persistent seizures will become malignant and selfsustaining refractory to standard pharmacotherapy. To date, there is no consensus on treating comatose patients with refractory NCSE, and the treatment mostly follows the guidelines on management of refractory generalized convulsive SE (GCSE). [3] [4] [5] When anesthetic agents involving g-aminobutyric acid (GABA) receptors fail to stop ongoing seizures and prevent their recurrence, a non-competitive N-methyl-D-aspartate (NMDA) antagonist, ketamine, has been successfully used in animal models and a few human cases, based on the theory of an imbalance of neuronal transmission by a predominance of excitatory receptors if seizures are continued. [6] [7] [8] Ketamine is currently used as an anesthetic agent for short operations, pediatric or veterinary surgeries, and also for chronic pain control. In the past, the clinical use of ketamine in control refractory SE was mostly via an intravenous route, and oral ketamine therapy has been documented only in pediatric patients with NCSE. 9 Herein we report the successful experience of oral ketamine use in terminating refractory complex partial status epilepticus in an elderly patient.
Case report
A 76-year-old woman was admitted to our neurological ward for prolonged disturbed consciousness over 12 h after cessation of a generalized convulsion by intravenous (IV) lorazepam at the emergency unit. She had recurrent ischemic, hemorrhagic strokes and bilateral traumatic subdural hemorrhages before this admission, and vascular dementia and a dependent life for 1 year. She had complex partial seizures characterized by right hand twitches and blank staring for 2 months, and used carbamazepine intermittently. Upon admission, she was in a profound stuporous state and had persistent clonic twitches or choreatic movements of her right hand and forearm at a frequency of about 1-2 Hz. An emergency electroencephalogram (EEG) showed periodic lateralized epileptiform discharges (PLED) with high-amplitude polyspikes recurring Nonconvulsive status epilepticus (NCSE) is a heterogeneous disorder with different seizure types and diverse etiologies, and is mainly characterized by altered consciousness. The recognition of NCSE is more challenging than generalized convulsive SE, and diagnosis and treatment are often delayed. Therefore, some cases can evolve into refractory SE and become pharmacoresistant even with GABAergic anesthetics. Herein we report the successful clinical experience of pharmacoresistant complex partial SE treated with ketamine. An elderly woman was profoundly stuporous and had relentless clonic movements of the right hand and forearm. Electroencephalography revealed repetitive periodic lateralized epileptiform discharges (PLEDs). There was a poor clinical response to standard anticonvulsants and GABAergic anesthetics. Both the clinical and electroencephalographic SE were controlled after intravenous ketamine therapy. Rebound refractory NCSE occurred about six days after discontinuing the intravenous ketamine, which was successfully terminated by oral ketamine treatment. There were no adverse effects observed.
ß 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. every 1-2 s on the left hemisphere, and main epileptic focus on the left anterior frontal area (Fig. 1a) . Brain magnetic resonance images (MRI) revealed old ischemic and hemorrhagic lesions, residual subdural hematoma and diffuse brain atrophy. A series of hematological, biochemistry and hormone studies revealed only a urinary tract infection. Under the impression of complex partial status epilepticus (CPSE) provoked by systemic infection and inadequate medicine control, she was first treated with intravenous (IV) valproic acid (bolus of 40 mg/kg, then 400 mg every 6 h with a blood level reaching 98 mg/mL) with no clinical improvement.
Midazolam anesthesia (initial dose of 0.4 mg/kg/h) was added soon after her airway had been protected, but it failed to reach burstsuppression (BS) on EEG even under a higher dosage (up to 1 mg/kg/ h). Oral levetiracetam (2000 mg/d/os) on day 2 and IV phenytoin (bolus of 20 mg/kg, then 300 mg/d) on day 3 were tried, however SE continued. In order to achieve a better suppression of clinical and EEG seizure activities, propofol anesthesia (up to 5 mg/kg/h) was substituted on day 4. The patient fell into a deeper coma state but there were still relentless subtle focal motor seizures of the right hand, and meanwhile her EEG showed near-total suppression and intermittent bursts of high-voltage spikes at the left frontal area (Fig. 1b) . From the initiation of propofol treatment, remarkable hypotension and stagnant bowel movements were observed, and an inotropic agent had to be given to stabilize the hemodynamic condition. The systemic side effects worsened and propofol anesthesia was withdrawn on day 6. Because thiopental was not available and the generic brand of phenobarbital in our hospital could not be given through an IV route, intramuscular (IM) phenobarbital was administered (100 mg every 4 h) after propofol had been stopped. In the meantime, IV valproic acid and lamotrigine (slow titrating dose starting with 50 mg/d/os) were maintained, and other standard anticonvulsants including oral carbamazepam (600 mg/d/os) and vigabatrin (2000 mg/d/os) were ineffective. Unfortunately, acute hepatitis with elevated liver enzymes and skin rash developed subsequently, and we had to discontinue the valproic acid and lamotrigine. Ultimately, she was maintained on phenobarbital (IM, 600 mg/d) and topiramate (200 mg/d/os) and the clinical and EEG SE persisted. Follow-up image studies including diffusion weighted images (DWI) and fluid-attenuated inversion recovery images (FLAIR) disclosed an edematous change with a faint bright signal on the left frontal cortex after prolonged seizures ( Fig. 2a and b) , which was not enhanced by contrast medium. Intravenous ketamine was added on the ninth day with the family's consent. The initial dose of ketamine was 1.5 mg/kg IV bolus continuously infused with a gradual dose titration from 0.05 mg/kg/h to 0.4 mg/kg/h. The SE pictures on EEG resolved gradually from day 12 with diffuse low amplitude delta waves on the left hemisphere and diffuse theta rhythms on the right hemisphere (Fig. 1c) . The patient woke and was able to move her limbs weakly when the total dose of ketamine reached 2000 mg. The infusion rate was weaned off when the total given dose was 2500 mg (about 50 mg/kg), and the respirator was disconnected smoothly. After removing the endotracheal tube, she was maintained with phenobarbital (180 mg/d/os) and topiramate (200 mg/d/os), and there were still brief complex partial seizures noted with durations of about 1-2 min about 2-3 times each day. At the same time, she was found to be suffering from bronchopneumonia related to the long hospital stay. Unfortunately, she gradually lapsed into a stupor with PLEDs reoccurring on EEG 6 days after discontinuing ketamine (Fig. 1d) . We assumed that the rebound status epilepticus was provoked by nosocomial infection and inadequate control with oral antiepileptics. Valproic acid (IV, maximal dose, 1600 mg/d) was infused immediately, and oral levetiracetam (2000 mg/d/os) was again tried but in vain. Both the clinical complex partial status epilepticus and PLEDs on EEG continued, and elevated liver enzymes were detected again 3 days after valproic acid treatment. A broad-spectrum antibiotic was substituted, and the dosage of antiepileptics was raised (phenobarbital, 400 mg/d IM, and topiramate, 300 mg/d per os). This time, we had to give up intravenous anesthetics to avoid reintubation on her family's request, and we decided to add oral ketamine (50 mg twice daily) via a nasogastric tube. Both the clinical SE and EEG SE began to improve from the third day of oral ketamine therapy. The EEG regained diffuse theta waves on the left and right hemispheres (Fig. 1e) when the total oral ketamine dose reached 1500 mg. Her condition and EEG remained stable after the total given dose reached 2000 mg, and oral ketamine was completely withdrawn shortly thereafter. No complex partial seizures were observed under the combination treatment of phenobarbital (180 mg/d/os) and topiramate (200 mg/d/os). The patient was discharged smoothly after her systemic infection and physical condition improved.
Discussion
Nonconvulsive status epilepticus is well known to be heterogeneous with diverse etiologies, different seizure subtypes, and varied prognosis. There is a common consensus that NCSE should be treated promptly and effectively to avoid brain damage or further evolution into generalized convulsive state. Because the diagnosis and treatment are often delayed, some cases become refractory status epilepticus. In this situation, the use of anesthetic agents as recommended in convulsive SE treatment is sometimes questionable. 10 The decision is difficult, especially when the patients with refractory NCSE have a stable hemodynamic condition because invasive procedures including intubation and ventilator support are inevitable when GABAergic anesthetics are added. 11 Therefore anesthetic treatment in refractory NSCE is usually deferred, and the seizures may become pharmacoresistant. The iatrogenic problems ensue when GABAergic anesthetics are used over a period of time.
Electroencephalography is imperative in diagnosing NCSE.
1,2,12
EEG with NCSE is typically documented with repetitive generalized or focal spikes, polyspikes, or spike-slow wave complexes, and some show rhythmic slow waves with evolution in voltage or frequency. 9, [13] [14] [15] [16] Characteristically, the EEG ictal pictures improve after lorazepam or anticonvulsant treatments. In our case, EEG showed continual PLED activities with periodic polyspikes and slow wave complexes occurring every 1-2 s, which were regarded as ictal during the whole disease course. The PLEDs resolved when her clinical condition improved. PLEDs are usually seen in acute unilateral or localized lesions such as infarcts, encephalitis and tumors, and the clinical picture is often complicated with conscious change. Over 80% of patients with PLEDs have been reported to have seizures during acute illness. 17 It is questionable whether PLEDs represent an ictal period, ictal-interictal continuum or just a transitional state of cortical irritability if acute structural lesions exist, and whether PLEDs are diagnostic in patients with NCSE is still under debate. 2, 12 EEG is also important in surveying the treatment effects. As in our case, in the varying degrees of burst-depression induced by different GABAergic anesthetics, the focal epileptic discharges persisted even in the brief burst periods. The persistent epileptic activities on EEG implied that the GABAergic anesthetics were ineffective after prolonged seizures. It was evidenced that every time the anesthetic anticonvulsants were stopped, both clinical SE and EEG SE reappeared. It has been proven that after repetitive seizures, GABA A receptors undergo internalization into the cells and decrease in number in the synaptic membrane, and in contrast NMDA receptors are recruited into the membrane. [6] [7] [8] According to this phenomenon in self-sustaining SE, combining therapy with NMDA antagonists to correct the imbalanced neuronal transmission is reasonable. [18] [19] [20] Ketamine, which binds noncompetitively to the phencyclidine site of the NMDA receptor, is a commercially available NMDA antagonist. The synergistic effects on refractory SE have been reported in rat models and human cases when used in combination with anesthetics modulating GABAergic receptors. 13, 14, 16, 21, 22 Because there is no consensus on intravenous ketamine treatment and protocol in malignant SE, the treatment in our elderly patient was modified from the recommendations provided by Wasterlain et al. and reports on young adult cases. 4, 13, 15, 16, 23 After a bolus dose and then a low steady infusion dose, the persistent PLEDs on the patient's EEG gradually disappeared. However, there were still several complex partial seizures observed daily when IV ketamine was stopped, and the patient suffered from another systemic infection. The patient's rebound SE was diagnosed rapidly under close clinical and EEG monitoring. We assumed that the relapse was provoked by uncontrolled systemic infection and inadequate oral antiepileptics. This time, the similar pharmacoresistant situation was treated promptly. We found that oral ketamine therapy offered the same cumulative therapeutic effect, which was as remarkable as the intravenous route. 24 Oral ketamine has been used as an analgesic adjuvant in a variety of chronic pain syndromes for years, and the analgesic effect is primarily based on the antagonism of NMDA receptors. 25 Although the bioavailability of ketamine given orally is only 16%, its primary active metabolite, norketamine, is also an NMDA antagonist. 26, 27 Norketamine has lesser affinity to NMDA receptors, but contributes significantly to the clinical effects, especially following oral administration. Ketamine has lesser suppressing effects in respiration and anesthesia, but is known to have psychomimetic side effects and probable neurotoxicity at high doses. In our case, no significant neurotoxicity was observed, although the patient was elderly and partially neurologically handicapped.
In conclusion, ketamine was effective and safe in controlling refractory and malignant NCSE in our elderly patient. If intravenous ketamine is not suitable under the invasive procedures on the respiratory tract, oral administration of ketamine is an effective alternative.
